Inflammatory Bowel Diseases Clinical Trial
Official title:
Von Willebrand Antigen and Activity as Novel Biomarkers of Hemostasis in Inflammatory Bowel Disease
The investigators are going to study von Willebrand antigen and activity levels in patients
with inflammatory bowel disease. The study will be on 46 patients who were diagnosed with
inflammatory bowel disease mainly ulcerative colitis and Crohn's disease divided into two
arms; group A will include 23 cases with active IBD(cases)status and group B will include 23
cases with inactive IBD status(control) to compare the vWF antigen and activity ( expected to
be higher in active disease group.
The investigators will follow all of the patients for any arterial or venous thrombosis to
evaluate IBD as a risk factor of thrombosis, on the other hand, they are looking to detect
cases of acquired von Willebrand syndrome in some cases with bleeding that not explained by
the inflammatory bowel disease status.
The aim of the work:
1. Assessment of VWF antigen in patients with inflammatory bowel disease and correlate it
to disease activity.
2. Evaluation of VWF antigen as a risk factor for thrombosis in inflammatory bowel disease
patients.
3. Detection of acquired von Willebrand disease in inflammatory bowel disease.
VWF is a high-molecular-weight multimeric glycoprotein, synthesized and released by vascular
endothelial cells and megakaryocytes that play an important role in platelet-endothelial cell
interaction and stabilizing the factor VIII (FVIII) coagulation protein.
Von Willebrand factor (VWF) is an acute-phase protein and a marker of endothelial damage.
VWF is crucial for platelet adhesion and aggregation. High-molecular weight multimers (HMWMs)
are involved in platelet aggregation under high shear stress but under normal conditions it
presents solely in the subendothelium and released into the bloodstream following activation
of endothelial cells.
Coagulation and inflammation are simultaneously activated and respond in synergy as a
preserved mechanism to repair the injured areas during tissue damage.
This observation is particularly relevant in acute inflammatory diseases, such as sepsis, but
it also seems to be very important in chronic inflammatory conditions, such as inflammatory
bowel disease.
Inflammatory bowel disease (IBD) with its two main forms, ulcerative colitis (UC) and Crohn
disease (CD), is a chronic inflammatory condition characterized by local and systemic
inflammation predominantly affecting the gastrointestinal tract and well known to be
associated with a hypercoagulable state and subsequently with an increased risk for venous
thromboembolism (VTE).
Thromboembolic complications such as Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE)
represent amongst IBD complications an important and underestimated factor to be borne in
mind which can significantly influence patient's morbidity and mortality.
In fact, according to the latest population-cohort studies, a 2 to 3-time fold increased risk
of developing of thromboembolic complications was reported for IBD patients compared to
general population.
In particular as Grainge., et al. and Papa., et al. both demonstrate in their studies, the
incidence of thromboembolic events varies depending on the activity phase of the disease,
suggesting that there is a higher risk of thromboembolic complications especially during IBD
flares, with similar relative risk values for both Crohn's Disease and Ulcerative Colitis.
Although the causes of the increased risk of VTE in IBD are not yet completely understood,
endothelial dysfunction has been demonstrated in IBD and it is evident through increasing
levels of endothelial injury markers. The most frequently used biochemical markers of
endothelial damage include von Willebrand factor (vWF), TM, vascular cell adhesion molecule 1
(VCAM-1), intercellular adhesion molecule 1 (ICAM-1) and endothelin-1 (ET-1).
In 2017 Cibor et al published the first report of the effects of parameters associated with
the structure and function of VWF on hemostasis in IBD. On the one hand, ADAMTS13: Ag was
lower in IBD patients than in controls, particularly in subjects with UC; this resulted in an
increased number of circulating multimers of VWF and thus an elevated thrombotic risk. The
prothrombotic effects are enhanced by markedly elevated VWF: Ag.
On the other hand, the incidence of AVWS, which leads to an increased risk for bleeding, was
higher in IBD patients. These findings provide insight into the elevated risk for
thromboembolic events and bleeding observed in UC and less frequently in CD. The
dysregulation of the balance between VWF function and ADAMTS13 reported herein might
contribute to the complex hemostatic abnormalities observed in IBD.
Currently, the association between CD and AVWS is likely underestimated, especially in cases
of acute bleeding not related to disease activity.
In 2017 Di Sabatino, et al reported three cases of IBD patients, who developed severe
hemorrhagic manifestations due to the concomitant presence of an AVWS, in addition to other
three cases was described in the literature. Such a condition can be life-threatening and its
timely identiļ¬cation is mandatory to adopt the optimal therapeutic strategy.
The association between AVWS and IBD might be more frequent than expected. The autoimmune
pathogenesis of IBD makes the association more likely. The availability of specialized
coagulation centers and correlation with clinical information should confirm the diagnosis.
Methodology:
Patients will be subjected to the following:
Clinical assessment:
1. The clinical assessment will include demographic data, the presence of comorbidities,
cigarette-smoking habits, previous history of thromboembolism and medications.
2. Body mass index (BMI) will be calculated for all patients.
3. In patients with CD and UC, the following parameters will be evaluated: disease
duration, disease location, disease activity, complications, and past surgical
procedures. Complications are defined as abscesses, fistulae, and stenoses.
4. Disease activity will be assessed according to ECCO-ESGAR Consensus Guidelines 2018.
Laboratory assessment:
The following will be done for all patients:
1. WBC, hematocrit, platelet count.
2. partial activated thromboplastin time.
3. C-reactive protein (CRP), and fecal calprotectin.
4. VWF: Ag, VWF: RCo and VWF: CB.
Radiological tests:
In cases with suspected arterial or venous thromboembolism, the appropriate radiological
study will be done (i.e. venous doppler for deep venous thrombosis).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Active, not recruiting |
NCT04990258 -
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
|
||
Completed |
NCT06216223 -
Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients
|
N/A | |
Enrolling by invitation |
NCT06015789 -
Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
|
||
Recruiting |
NCT06065995 -
StoMakker Mobile Application
|
N/A | |
Recruiting |
NCT03282786 -
Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease
|
N/A | |
Recruiting |
NCT06002074 -
SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT04960826 -
Study of an Environmental Risk Factor in Crohn's Disease
|
||
Recruiting |
NCT05413941 -
Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Completed |
NCT00721812 -
A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686
|
Phase 1 | |
Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Recruiting |
NCT04991324 -
Cholecalciferol Comedication in IBD - the 5C-study
|
Phase 3 | |
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Not yet recruiting |
NCT05043818 -
A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
|
||
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A |